Wells Fargo & Company MN Sells 414,528 Shares of AstraZeneca (AZN)

Wells Fargo & Company MN decreased its stake in AstraZeneca (NYSE:AZN) by 9.6% during the first quarter, according to its most recent disclosure with the Securities & Exchange Commission. The fund owned 3,886,709 shares of the company’s stock after selling 414,528 shares during the quarter. Wells Fargo & Company MN owned approximately 0.15% of AstraZeneca worth $135,919,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Atria Investments LLC raised its holdings in AstraZeneca by 26.3% in the 4th quarter. Atria Investments LLC now owns 33,495 shares of the company’s stock worth $1,162,000 after purchasing an additional 6,979 shares during the period. Bank of Montreal Can raised its holdings in AstraZeneca by 243.4% in the 4th quarter. Bank of Montreal Can now owns 415,126 shares of the company’s stock worth $14,404,000 after purchasing an additional 294,246 shares during the period. Ingalls & Snyder LLC acquired a new position in AstraZeneca in the 4th quarter worth about $865,000. Fisher Asset Management LLC raised its holdings in AstraZeneca by 2.7% in the 4th quarter. Fisher Asset Management LLC now owns 11,917,332 shares of the company’s stock worth $413,531,000 after purchasing an additional 315,759 shares during the period. Finally, Flagship Harbor Advisors LLC acquired a new position in AstraZeneca in the 4th quarter worth about $227,000. Hedge funds and other institutional investors own 15.59% of the company’s stock.

A number of research firms recently weighed in on AZN. ValuEngine cut AstraZeneca from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 7th. BMO Capital Markets reaffirmed a “buy” rating and issued a $38.00 price target on shares of AstraZeneca in a report on Friday, January 26th. Zacks Investment Research raised AstraZeneca from a “sell” rating to a “hold” rating in a report on Tuesday, March 20th. Jefferies Group raised AstraZeneca from a “hold” rating to a “buy” rating and upped their price target for the stock from $28.43 to $36.70 in a report on Monday, March 19th. Finally, Sanford C. Bernstein upped their price target on AstraZeneca from $40.00 to $42.00 and gave the stock an “outperform” rating in a report on Monday, February 5th. Three equities research analysts have rated the stock with a sell rating, five have given a hold rating and thirteen have given a buy rating to the stock. AstraZeneca presently has an average rating of “Hold” and an average price target of $38.12.

Shares of AstraZeneca stock opened at $36.33 on Monday. AstraZeneca has a 12 month low of $28.43 and a 12 month high of $36.75. The company has a market cap of $92.02 billion, a price-to-earnings ratio of 8.49, a PEG ratio of 1.94 and a beta of 0.61. The company has a quick ratio of 0.62, a current ratio of 0.80 and a debt-to-equity ratio of 0.93.

AstraZeneca (NYSE:AZN) last announced its earnings results on Friday, May 18th. The company reported $0.48 EPS for the quarter, beating analysts’ consensus estimates of $0.28 by $0.20. AstraZeneca had a return on equity of 30.12% and a net margin of 12.61%. The business had revenue of $5.18 billion during the quarter, compared to analysts’ expectations of $5.24 billion. During the same quarter in the prior year, the firm earned $0.99 earnings per share. The business’s revenue was down 4.2% compared to the same quarter last year. equities research analysts anticipate that AstraZeneca will post 1.7 EPS for the current fiscal year.

AstraZeneca Profile

AstraZeneca PLC discovers, develops, and commercializes prescription medicines for the treatment of oncology, cardiovascular and metabolic, respiratory, gastrointestinal, neuroscience, and infection diseases worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor2, Plendil, Seloken/Toprol-XL4, Tenormin5, and Zestril6 for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca (NYSE:AZN).

Institutional Ownership by Quarter for AstraZeneca (NYSE:AZN)

Receive News & Ratings for AstraZeneca Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca and related companies with MarketBeat.com's FREE daily email newsletter.



Leave a Reply